LB057 - ASSESSING PRACTICAL SCREENING TOOLS FOR SARCOPENIA IN STABLE DECOMPENSATED CIRRHOSIS: A CROSS-SECTIONAL STUDY

LB057

ASSESSING PRACTICAL SCREENING TOOLS FOR SARCOPENIA IN STABLE DECOMPENSATED CIRRHOSIS: A CROSS-SECTIONAL STUDY

W. Manasirisuk1,*, T. Kuichanuan1, V. Pisprasert1, J. Inthanon1, J. Jinchai1

1Department of medicine, Khon Kaen University, Khon Kaen, Thailand

 

Rationale: To evaluate the validity of sarcopenia screening tools in stable decompensated cirrhosis.

Methods: A cross-sectional study included patients with stable decompensated cirrhosis attending the outpatient gastroenterology and hepatology clinic at Srinagarind Hospital, Khon Kaen University, from April 2022 to August 2024. Sarcopenia was diagnosed using the 2019 Asian Working Group for Sarcopenia criteria, with bioelectrical impedance analysis for muscle mass assessment. The validity of calf circumference, SARC-F, SARC-Calf, the Yubi-wakka test, and modified MSRA-5 were evaluated.

Results: Among 64 patients (mean age: 60 years; 70% male), 81% were classified as Child-Pugh class A. Sarcopenia was identified in 23 patients (35.9%). The modified MSRA-5 and Yubi-wakka tests demonstrated the highest sensitivity, at 65.2% (95% CI: 42.7–83.6) and 56.5% (95% CI: 34.5–76.8), respectively. The Yubi-wakka test and calf circumference exhibited the highest negative predictive values, at 76.2% (95% CI: 60.5–87.9) and 75.0% (95% CI: 59.7–86.8), respectively. The Yubi-wakka test and calf circumference were significantly associated with sarcopenia, with areas under the receiver operating characteristic curve (AUC) values of 0.67 (95% CI: 0.55–0.80) and 0.66 (95% CI: 0.54–0.78), respectively. Notably, the calf circumference demonstrated the highest AUC in males, at 0.72 (95% CI: 0.57–0.87). Our proposed cut-off for calf circumference in males was <35.75 cm, which increased the AUC to 0.81 (95% CI: 0.71–0.92).

Conclusion: Calf circumference and the Yubi-wakka test demonstrated acceptable diagnostic performance for sarcopenia in stable decompensated cirrhosis, highlighting their potential as simple and practical bedside screening tools. Further validation in larger cohorts is warranted.

References: Chen LK, Woo J, Assantachai P, Auyeung TW, Chou MY, Iijima K, et al. Asian Working Group for Sarcopenia: 2019 Consensus Update on Sarcopenia Diagnosis and Treatment. J Am Med Dir Assoc. 2020;21:300-307.e2. 

Disclosure of Interest: None declared